Tolvaptan for Autosomal Dominant Polycystic Kidney Disease: Pharmacokinetics and Implications for Practice

Credits: None available.
Type: Article
Authors:
  • Cheryl B. Hines, EdD, MSN, CRNA
  • Gwendolyn L. Hooper, PhD, APRN-BC, FNP, CUNP
  • Angela Collins-Yoder, PhD, RN, CCNS, ACNS, BC, SCRN
Tags: infection end stage renal disease renal stones tolvaptan vasopressin-2 receptor antagonist autosomal dominant polycystic kidney disease kidney cysts renal capsule